AV8 Ventures

AV8 Ventures is the $360 million early-stage fund backed by Allianz, the European insurance giant, with operations split between Palo Alto and the United Kingdom. The firm invests across healthcare, enterprise, financial services, and deep tech, with healthcare as one of four core verticals. The Allianz backing matters: AV8 is a corporate-affiliated fund that brings strategic insurer relationships into its portfolio while running a financial-returns mandate. For founders building deep tech and AI-native healthcare companies, particularly in regulated diagnostics and clinical software, AV8 sits in a distinctive corner of the early-stage market.

The stated thesis is investing in deep tech across regulated industries, with healthcare representing one of the firm’s primary verticals. Within digital health, medical devices and MedTech, diagnostics, health IT and healthcare software, and AI and machine learning in healthcare, AV8 targets companies whose technical or scientific differentiation is meaningful and whose go-to-market strategy navigates the regulatory and contractual complexity of established healthcare buyers. The firm is comfortable as both lead and co-investor, and the Allianz relationship can unlock strategic conversations with one of the largest insurance and asset management organizations in the world. Founders should expect a partner who will press hard on technical defensibility, regulatory pathway, and strategic fit with insurer or institutional buyers.

The healthcare portfolio includes Delfi Diagnostics, the cancer detection company developing fragmentomics-based blood tests; Alpha Medical, the women’s health telehealth platform; SimBioSys, the AI-native cancer modeling company; Yuvo Health, the value-based care platform serving community health centers; Cerby, the identity security platform with healthcare applications; and Embrace, the consumer health and parenting platform. The pattern across these companies is technical or scientific differentiation, regulatory complexity, and a customer base that includes payers, providers, and large institutions. AV8 has been particularly active in AI-native diagnostics and in tech-enabled care delivery aligned to value-based contracting.

Check sizes are in the $5 million to $25 million range at Seed and Series A, which positions AV8 as a credible lead at meaningful early-stage rounds. The capital stack positioning is that of a deep tech early-stage lead with a strategic insurer relationship, which is a useful combination for healthcare founders whose business depends on payer or insurer adoption. The firm is comfortable leading priced Series A rounds and participating in larger Series B rounds where their thesis remains intact. Reserves are sized for follow-on participation, and the Allianz relationship can extend the strategic surface area of the partnership across multiple rounds.

The team includes Managing Director and General Partner George Ugras, Venture Partner for Healthcare Ruchita Sinha, Venture Partner for Enterprise Shawn Kung, Venture Partner for GTM Brett Battles, and Operating Partner Serpil Kuyucak. Ruchita Sinha is the primary healthcare contact and has been the lead voice on the firm’s healthcare practice. Decision-making is partner-led and incorporates strategic input from Allianz, but the firm is structured to make financial-returns decisions on its own without requiring corporate alignment on every investment. Founders should expect a thorough technical and commercial diligence process.

The most reliable path into AV8 is a warm introduction from a portfolio CEO, a healthcare operator in the firm’s network, or an investor who has co-invested with the firm. Introductions through Allianz operating leaders and through European insurer networks are also effective, particularly for companies whose business model has insurance relevance. Cold outreach to Ruchita Sinha for healthcare-specific opportunities is read and converted at a higher rate than at typical generalist firms, given the firm’s deep tech focus and narrower sourcing universe. Communication after first contact is rigorous and structured.

Approach AV8 when you are building a deep tech healthcare company, particularly in AI-native diagnostics, regulated clinical software, or value-based care, and when a strategic insurer relationship would meaningfully accelerate your business. Do not approach when you are building a pure consumer wellness brand without technical differentiation, when you need a brand-forward consumer investor, or when you are raising a smaller seed that does not justify a $5 million-plus check. AV8 is a deep tech, insurer-affiliated early-stage lead for the founders building technically and clinically rigorous healthcare companies.